| Literature DB >> 23746878 |
Nobuhiro Asai1, Yoshihiro Ohkuni, Ikuo Yamazaki, Norihiro Kaneko, Masahiro Aoshima, Yasutaka Kawamura.
Abstract
Combination therapy of CT-guided percutaneous drainage and antibiotics is the first-line treatment for abscesses. Its effectiveness has been demonstrated. However, the therapeutic impact of this procedure for infection treatment has never been reported. We retrospectively analyzed all 47 patients who received CT-guided percutaneous drainage for infection treatment. Patients' characteristics, pathogens isolated, antibiotics administered, technical and clinical outcomes, complications related to this procedure and therapeutic impacts were investigated. Patients were 26 males and 21 females. The mean age was 63.5 years (±18.7). The diseases targeted were 19 retroperitoneal abscesses, 18 intra-abdominal abscesses, three pelvic abscesses, and seven others. As for technical outcomes, all of the 54 procedures (100%) were successful. As for clinical outcomes, 44 (93.6%) were cured and three patients (6.4%) died. No complications related to this procedure were found in this study. A total of 42 patients (88%) had a change in the management of their infection as a result of CT-guided percutaneous drainage, such as selection and discontinuation of antibiotics. In conclusion, CT-guided percutaneous drainage is a safe and favorable procedure in the treatment of deep tissue abscesses. Therapeutic impact of these procedures helped physicians make a rational decision for antibiotics selection.Entities:
Keywords: Abscess; CT-guided percutaneous drainage; Infection
Mesh:
Year: 2013 PMID: 23746878 PMCID: PMC9428062 DOI: 10.1016/j.bjid.2012.12.008
Source DB: PubMed Journal: Braz J Infect Dis ISSN: 1413-8670 Impact factor: 3.257
Patients’ characteristics.
| Variables | All patients ( |
|---|---|
| 26/21 | |
| 63.5 (±18.7) | |
| | 15–87 |
| | 19 |
| Iliopsoas abscess | 13 (27.7%) |
| Renal abscess | 4 |
| Pancreatic abscess | 2 |
| | 18 |
| | 3 |
| | 7 |
| | 9 (19.1%) |
| | 13 (27.7%) |
| | 12 (25.5%) |
| | 15 (31.9%) |
| | 54 (100%) |
| | 0 (0%) |
| | 44 (93.6%) |
| | 3 (6.4%) |
| | 38 (80.9%) |
| | 12/39 (30.8%) |
| | 33 (70.2%) |
| | 38 |
| | 2–168 (±30.2) |
| | 27 |
| | 5 |
| | 6 |
| | 8 |
| | 1 |
| | 14 (29.8%) |
| | 62.7 |
| | 19–169.2 (±31.8) |
| | 38 (80.9%) |
| | 20 (42.6%) |
| | 18 (38.3%) |
| | 13 |
| | 7 |
| | |
| Oxacillin susceptible | 6 |
| Oxacillin resistant | 1 |
| | 5 |
| | 3 |
| | 3 |
| Koseri | 1 |
| | 1 |
| Constellatus | 2 |
| Sanguis | 1 |
| Milleri | 2 |
| | 1 |
| | 4 |
VCM, vancomycin; NQs, new quinolones.
Others include thoracic abscesses and splenic abscess.
Others include Peptococcus species, Proteus mirabilis, Enterococcus raffinosus, Lactobacter species.
Comparison between survivors and non-survivors.
| Variables | Non-survivors ( | Survivors ( | |
|---|---|---|---|
| 2/1 | 23/21 | 1.000 | |
| Age (±SD) | 62.1 (±4.7) | 83.3 (±18.9) | 0.062 |
| Duration of antibiotics (days) | 27 (±20.3) | 39.5 (±31.3) | 0.504 |
| De-escalation | 2 (66.7%) | 11 (23.4%) | 0.181 |
| 3 (100%) | 35 (79.5%) | 0.61 | |
| Malignancy | 2 | 14 | 0.264 |
| Diabetes mellitus | 1 | 8 | 0.48 |
| Vertebral disease | 1 | 12 | 0.57 |
| Renal disease | 2 | 10 | 0.156 |
SD, standard deviation.